- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07941583
A Phase II Study of Ivonescimab Combined With Iza-bren in Patients With Advanced Non-Small Cell Lung Cancer. (PEGASUS-Lung)
A Multicenter, Single-Arm, Phase II Study Evaluating the Efficacy and Safety of Ivonescimab Combined With Iza-bren Brengitecan in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Resistant to Third-Generation EGFR-TKIs
This is a prospective, multicenter, open-label, single-arm phase II clinical study evaluating the efficacy and safety of ivonescimab (a PD-1/VEGF bispecific antibody) combined with Iza-bren (BL-B01D1; izalontamab brengitecan, an EGFR×HER3 bispecific antibody-drug conjugate) in patients aged ≥18 years with histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous non-small cell lung cancer (NSCLC) harboring EGFR-sensitizing mutations (exon 19 deletion or L858R) who have imaging-confirmed disease progression during or after prior third-generation EGFR-TKI therapy. A total of 43 subjects will be enrolled at 3 centers. The primary endpoint is progression-free survival (PFS). Other efficacy endpoints include ORR, confirmed ORR, DCR, DoR, OS, 6- and 12-month PFS rates, and 12- and 24-month OS rates. Safety and tolerability will be assessed, and exploratory analyses will evaluate immune markers, HER3 expression, and EGFR resistance molecular subtypes in relation to clinical efficacy. Treatment is given every 3 weeks: ivonescimab 20 mg/kg intravenously on Day 1; Iza-bren 2.5 mg/kg intravenously on Days 1 and 8. Ivonescimab is infused first, followed by Iza-bren after an interval of ≥30 minutes. Treatment continues until disease progression, intolerable toxicity, initiation of new anti-cancer therapy, death, withdrawal of consent, or a maximum of 24 months of treatment.
연구 개요
상세 설명
Study Design Prospective, multicenter, single-arm phase II study Objectives
Primary objective:
To evaluate the efficacy and safety of ivonescimab combined with Iza-bren in patients with EGFR-sensitizing mutation-positive advanced non-squamous NSCLC after progression on third-generation EGFR-TKIs.
Secondary objectives:
- To explore the correlation of baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy;
- To analyze efficacy differences in the baseline brain metastasis subgroup and among different EGFR mutation subtypes (19del/L858R);
- To explore the association of tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) with PFS and OS outcomes.
Endpoints
- Progression-free survival (PFS), objective response rate (ORR), confirmed objective response rate (cORR), and overall survival (OS); to calculate 6-month and 12-month PFS rates and 12-month and 24-month OS rates;
- To evaluate the overall safety and tolerability of the combination regimen, and to describe the type, incidence, severity (CTCAE 6.0), duration, management measures, and outcomes of treatment-related adverse events (TRAEs).
Study Population Pathologically confirmed non-squamous NSCLC harboring EGFR-sensitizing mutations, with imaging-confirmed progression after third-generation EGFR-TKI therapy (age ≥18 years, any sex).
Inclusion/Exclusion Criteria
Inclusion criteria (all must be met):
-
Voluntary written informed consent and ability to comply with study procedures; age ≥18 years, any sex.
-
Histologically or cytologically confirmed unresectable locally advanced (stage IIIB/IIIC) or metastatic (stage IV) non-squamous NSCLC (AJCC 8th edition).
-
EGFR-sensitizing mutation (exon 19 deletion or L858R) confirmed by tissue, cytology, or plasma ctDNA; concomitant resistance mutations such as T790M, C797S, and 861Q are allowed.
-
Prior standard treatment with a third-generation EGFR-TKI (osimertinib, almonertinib, furmonertinib, etc.), with imaging-confirmed disease progression during or after treatment.
-
ECOG performance status 0 or 1; expected survival ≥3 months.
-
At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm; lymph node short diameter ≥15 mm).
-
Without transfusion or use of colony-stimulating factors, thrombopoietin, or any cell growth factor within 14 days before screening tests, organ function must meet the following criteria:
- Hematology: ANC ≥1.5×10⁹/L; PLT ≥75×10⁹/L; Hb ≥90 g/L;
- Liver function: AST/ALT ≤2.5×ULN (≤5×ULN in patients with liver metastases); total bilirubin ≤1.5×ULN;
- Renal function: creatinine ≤1.5×ULN; urine protein ≤2+ or ≤1000 mg/24 h;
- Coagulation: INR and APTT ≤1.5×ULN.
-
Toxicities from prior anti-cancer therapy have recovered to ≤ grade 1 per NCI-CTCAE v6.0 (except alopecia, fatigue, pigmentation, hypothyroidism stable on hormone replacement, grade 2 peripheral neuropathy after chemotherapy, and other exceptions specified in the inclusion criteria).
-
Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test is negative at screening for women of childbearing potential.
Exclusion criteria (any one excludes):
- Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
- Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
- Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
- Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
- Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
- Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
- Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
- QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
- Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
- Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
- Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
- Pregnant or lactating women.
- Concurrent participation in other interventional anti-cancer clinical trials.
- Investigator considers the patient unsuitable for participation in this study. Randomization and Intervention Plan Ivonescimab: 20 mg/kg, intravenous infusion on Day 1 of each cycle; first infusion time 60±10 minutes; for patients unable to tolerate a 60-minute infusion, the infusion time may be extended up to 120 minutes; if no infusion reaction occurs, subsequent cycles may be shortened to 30-60 minutes.
Iza-bren: 2.5 mg/kg, intravenous drip on Days 1 and 8 of each cycle; first infusion time ≥120 minutes; after tolerance, it may be adjusted to 60-120 minutes.
Follow-up Plan Treatment-period follow-up: once before each treatment cycle to assess safety and compliance; efficacy follow-up with imaging every 6 weeks.
End-of-treatment (EOT) visit: 28±7 days after the last dose; complete physical examination, laboratory tests, imaging assessment (conditional), and AE follow-up.
Survival follow-up: every 90±7 days after EOT, via outpatient visit, telephone, WeChat, etc.; record survival status, subsequent anti-cancer treatment, and living status.
Sample Size Calculation A total of 43 subjects are planned. Based on the one-sample log-rank method: the expected number of events under the alternative hypothesis is 32.26; with 38 subjects enrolled, the asymptotic power can reach 80.78%, meeting the prespecified power requirement; considering a 10% dropout rate, the final sample size is 43.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Fuming Qiu
- 전화번호: +86-13858005908
- 이메일: qiufuming@zju.edu.cn
연구 연락처 백업
- 이름: Youping Wang
- 전화번호: +86-18358147489
- 이메일: 2315124@zju.edu.cn
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
-
Voluntary written informed consent, age ≥18 years, any sex.
-
Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) non-squamous NSCLC (AJCC 8th edition).
-
Confirmed EGFR-sensitizing mutation (Exon 19 deletion or L858R) in tissue, cytology, or plasma ctDNA. Concomitant resistance mutations (e.g., T790M, C797S, 861Q) are allowed.
-
Prior standard treatment with a third-generation EGFR-TKI (e.g., osimertinib, almonertinib, furmonertinib), with imaging-confirmed disease progression during or after treatment.
-
ECOG performance status of 0 or 1; expected survival ≥3 months.
-
At least one measurable target lesion per RECIST v1.1 at baseline (longest diameter ≥10 mm, or lymph node short diameter ≥15 mm).
-
Adequate organ function (without transfusion or growth factors within 14 days prior to screening):
Hematology: ANC ≥1.5×10^9/L; PLT ≥75×10^9/L; Hb ≥90 g/L. Liver: AST/ALT ≤2.5×ULN (≤5×ULN for liver metastases); Total bilirubin ≤1.5×ULN.
Renal: Creatinine ≤1.5×ULN; Urine protein ≤2+ or ≤1000 mg/24h. Coagulation: INR and APTT ≤1.5×ULN.
-
Prior treatment-related toxicities have recovered to ≤ Grade 1 per NCI-CTCAE v6.0 (except for alopecia, fatigue, pigmentation, stable hypothyroidism on hormone replacement, or grade 2 peripheral neuropathy from chemotherapy).
-
Women of childbearing potential and male subjects agree to use effective contraception throughout the study and for 6 months after the last dose; serum pregnancy test must be negative for women of childbearing potential at screening.
Exclusion Criteria:
- Pathology containing small cell lung cancer components, or tumors predominantly large cell carcinoma or squamous cell carcinoma, except: curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, cervical carcinoma in situ, breast carcinoma in situ, and/or curatively resected carcinoma in situ that the investigator considers eligible.
- Known co-existing targetable driver gene alterations (e.g., MET amplification, ROS1 fusion, etc.) without prior corresponding targeted therapy. (Exception: Patients who are unable to receive such targeted therapy due to definitive medical contraindications, e.g., severe allergy or specific organ dysfunction, and have been strictly evaluated by the investigator).
- Isolated disease progression only (oligoprogression) that is suitable for and planned to receive local therapy (e.g., radiotherapy or surgery); or patients who have not developed new systemic progression after prior local therapy.
- Prior treatment with ivonescimab, Iza-bren, or other EGFR/HER3-ADC drugs.
- Active symptomatic interstitial lung disease; prior drug-induced interstitial pneumonia requiring intravenous steroid intervention.
- Uncontrolled active infection, sepsis, or concurrent pulmonary disease causing clinically severe respiratory impairment, including but not limited to: a. any underlying pulmonary disease (e.g., pulmonary embolism, severe asthma, severe chronic obstructive pulmonary disease within 3 months before randomization); b. restrictive lung disease; c. prior pneumonectomy; severe cardiovascular disease (heart failure, history of myocardial infarction, etc.); hepatic or renal failure.
- Hypertension uncontrolled by medication: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; myocardial infarction, stroke, or aortic dissection within the past 6 months; prior grade ≥3 arterial/venous thromboembolic event.
- QT interval prolongation (QTc >450 ms in men or QTc >470 ms in women, calculated using the Fridericia formula), complete left bundle branch block, third-degree atrioventricular block, frequent and uncontrollable arrhythmia (except those stable for 2 weeks after antiarrhythmic drug treatment): e.g., atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular flutter (transient atrial fibrillation/flutter excluded).
- Prior grade ≥3 bleeding event; imaging suggests tumor invasion of major vessels with high bleeding risk.
- Active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years; thyroid hormone replacement and topical steroids are not excluded.
- History of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Systemic anti-cancer therapy (chemotherapy, targeted therapy, immunotherapy) within 4 weeks before screening; major surgery or unhealed severe trauma within 4 weeks; palliative radiotherapy field must not include RECIST target lesions.
- Severe hypersensitivity to monoclonal antibodies or any component of ADC formulations.
- Pregnant or lactating women.
- Concurrent participation in other interventional anti-cancer clinical trials.
- Investigator considers the patient unsuitable for participation in this study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Ivonescimab combined with Izabren
Patients receive ivonescimab (20 mg/kg IV on Day 1) and Iza-bren (2.5 mg/kg IV on Days 1 and 8) every 3 weeks (21-day cycle). Treatment continues until disease progression, unacceptable toxicity, or up to 24 months. |
20 mg/kg, intravenous infusion on Day 1 of each 21-day cycle.
다른 이름들:
2.5 mg/kg, intravenous drip on Days 1 and 8 of each 21-day cycle. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Progression-Free Survival (PFS)
기간: From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).
|
PFS is defined as the time from the first dose of study treatment to the first documented disease progression (evaluated by investigators according to RECIST v1.1) or death from any cause, whichever occurs first. Participants who are alive and progression-free at the time of analysis will be censored at the last adequate tumor assessment. |
From the first dose of study treatment until disease progression or death from any cause (assessed every 6 weeks; up to 24 months of study treatment and 24 months of survival follow-up).
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Objective Response Rate (ORR)
기간: Up to approximately 24 months.
|
The proportion of participants with a best overall response of complete response (CR) or partial response (PR), as assessed by investigators according to RECIST v1.1. |
Up to approximately 24 months.
|
|
Confirmed Objective Response Rate (cORR)
기간: Up to approximately 24 months.
|
The proportion of participants with a confirmed CR or PR (confirmed by repeat imaging at least 4 weeks later), as assessed by investigators according to RECIST v1.1. |
Up to approximately 24 months.
|
|
Disease Control Rate (DCR)
기간: Up to approximately 24 months.
|
The proportion of participants with a best overall response of CR, PR, or stable disease (SD), as assessed by investigators according to RECIST v1.1. |
Up to approximately 24 months.
|
|
Duration of Response (DoR)
기간: From first documented response to disease progression or death (up to approximately 24 months).
|
The time from the first documentation of CR or PR to the first documentation of disease progression or death from any cause, whichever occurs first. |
From first documented response to disease progression or death (up to approximately 24 months).
|
|
Overall Survival (OS)
기간: From the first dose of study treatment to death from any cause (up to approximately 42 months).
|
The time from the first dose of study treatment to death from any cause. |
From the first dose of study treatment to death from any cause (up to approximately 42 months).
|
|
6-month and 12-month PFS Rates
기간: At 6, 12 months after the first dose.
|
The probability of participants remaining progression-free at specific time points, estimated using the Kaplan-Meier method. |
At 6, 12 months after the first dose.
|
|
12-month and 24-month OS Rates
기간: At 12 and 24 months after the first dose.
|
The probability of participants remaining alive at specific time points, estimated using the Kaplan-Meier method. |
At 12 and 24 months after the first dose.
|
|
Safety and Tolerability (Incidence of Treatment-Related Adverse Events)
기간: From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).
|
The incidence, severity (graded by NCI-CTCAE v6.0), duration, and management of treatment-related adverse events (TRAEs). |
From the first dose of study treatment until 28 days after the last dose (up to approximately 24 months of treatment).
|
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Correlation of Biomarkers with Clinical Efficacy
기간: Baseline, during treatment, and up to approximately 42 months.
|
To explore the correlation between baseline and on-treatment peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.), HER3 expression levels, and EGFR resistance molecular subtypes (T790M, C797S, MET amplification, etc.) with clinical efficacy (e.g., ORR, PFS). |
Baseline, during treatment, and up to approximately 42 months.
|
|
Efficacy Analysis in Specific Subgroups
기간: Up to approximately 42 months.
|
To analyze the differences in efficacy (such as ORR and PFS) among patients with baseline brain metastases and different EGFR mutation subtypes (exon 19 deletion vs. L858R). |
Up to approximately 42 months.
|
|
Association of Immune Markers with Survival Outcomes
기간: Up to approximately 42 months.
|
To explore the association between tumor tissue and peripheral blood immune markers (TILs, PD-L1, cytokine profiles, etc.) and survival outcomes (PFS and OS). |
Up to approximately 42 months.
|
공동 작업자 및 조사자
간행물 및 유용한 링크
일반 간행물
- Wei Q, Li P, Yang T, Zhu J, Sun L, Zhang Z, Wang L, Tian X, Chen J, Hu C, Xue J, Ma L, Shimura T, Fang J, Ying J, Guo P, Cheng X. The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors. J Hematol Oncol. 2024 Jan 4;17(1):1. doi: 10.1186/s13045-023-01509-2.
- HARMONi-A Study Investigators; Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, Zhao H, Li M, Li K, Song Q, Du X, Sun Y, Li W, Sun L, Wang Z, Yang K, Fan Y, Liu B, Zhao H, Hu Y, Jia L, Xu S, Yi T, Lv D, Lan H, Li M, Liang W, Wang Y, Yang H, Jia Y, Chen Y, Lu J, Shi M, Liu C, Zhou M, Zhou J, Liu X, Zhou N, He M, Dong X, Chen H, Chen Y, Su H, Li X, Zhang Z, Yang L, Liu Y, Chen L, Hou X, Zhang Y, Guo J, Ma R, Lu H, Wu D, Feng W, Li W, Huang J, Wang Y, Song X, Peng J, Liu L, Guo Y, Li W, Xia M, Lu D, Hu M, Wang ZM, Li B, Xia MY, Zhang L. Bispecific Antibody Ivonescimab Added to Chemotherapy in EGFR-Variant Non-Small Cell Lung Cancer: The HARMONi-A Randomized Clinical Trial. JAMA. 2026 Jul 28;336(4):306-314. doi: 10.1001/jama.2026.7745.
- Zhou K, Liu X, Zhu H. Overcoming resistance to antibody-drug conjugates: from mechanistic insights to cutting-edge strategies. J Hematol Oncol. 2025 Nov 3;18(1):96. doi: 10.1186/s13045-025-01752-9.
- Yu HA, Goto Y, Hayashi H, Felip E, Chih-Hsin Yang J, Reck M, Yoh K, Lee SH, Paz-Ares L, Besse B, Bironzo P, Kim DW, Johnson ML, Wu YL, John T, Kao S, Kozuki T, Massarelli E, Patel J, Smit E, Reckamp KL, Dong Q, Shrestha P, Fan PD, Patel P, Sporchia A, Sternberg DW, Sellami D, Janne PA. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy. J Clin Oncol. 2023 Dec 10;41(35):5363-5375. doi: 10.1200/JCO.23.01476. Epub 2023 Sep 10.
- Trontzas IP, He M, Wurtz A, Robbins CJ, Robinson N, Bates K, Liu M, Aung TN, Scott L, Chan N, Burela S, Schillo J, Liebler DC, Hill S, Morrison RD, Vathiotis I, Syrigos KN, Goldberg SB, Politi K, Rimm DL. Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-type Non-Small Cell Lung Cancer. Clin Cancer Res. 2025 Jul 1;31(13):2767-2776. doi: 10.1158/1078-0432.CCR-24-3347.
- Scharpenseel H, Hanssen A, Loges S, Mohme M, Bernreuther C, Peine S, Lamszus K, Goy Y, Petersen C, Westphal M, Glatzel M, Riethdorf S, Pantel K, Wikman H. EGFR and HER3 expression in circulating tumor cells and tumor tissue from non-small cell lung cancer patients. Sci Rep. 2019 May 15;9(1):7406. doi: 10.1038/s41598-019-43678-6.
- Gao L, Zhang Y, Feng M, Shen M, Yang L, Wei B, Zhou Y, Zhang Z. HER3: Updates and current biology function, targeted therapy and pathologic detecting methods. Life Sci. 2024 Nov 15;357:123087. doi: 10.1016/j.lfs.2024.123087. Epub 2024 Oct 2.
- Zhao J, Xu W, Zhou F, Zhang X, Zhou M, Miao D, Yu L, Zhang Y, Fan J, Zhou C, Li W, Mok T, Le X, Li M, Xia Y. Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC - mechanisms and evolving treatment approaches. Nat Rev Clin Oncol. 2026 Jan;23(1):63-83. doi: 10.1038/s41571-025-01085-z. Epub 2025 Nov 11.
- Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014 Aug;14(8):535-46. doi: 10.1038/nrc3775.
- Sung H, Filho AM, Laversanne M, Ferlay J, Siegel RL, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2024: GLOBOCAN estimates of incidence and mortality worldwide for 34 cancers in 186 countries. CA Cancer J Clin. 2026 Jul-Aug;76(4):e70090. doi: 10.3322/caac.70090.
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
- IIT-2026-10-22
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .